Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics

    Dr. Steve Pakola, CMO                     Tel: +1(212)201-0920
                                              steve.pakola@thrombogenics.com

    Dr. Patrik De Haes, CEO                   Tel: +32-16-75-13-10
                                              patrik.dehaes@thrombogenics.com

    Citigate Dewe Rogerson

    Amber Bielecka/ David Dible/ Nina Enegren Tel: +44(0)207-638-95-71
                                              amber.bielecka@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... better screening strategies can lower the rate of false-positive ... on women. The many misperceptions about breast cancer screening ... and the need for new approaches and better education ... supplement to Journal of Women,s Health , a ... supplement is available free on the Journal of ...
(Date:9/23/2014)... National Institutes of Health has awarded $10.1 million in ... to explore the effects of sex in preclinical and ... females and males, and is a catalyst for considering ... overreliance on male subjects in preclinical research can obscure ... human studies. This progressive approach will result in greater ...
(Date:9/23/2014)... BLOOMINGTON, Ind. -- Contrary to what is often assumed ... a new study from The Kinsey Institute has found ... and are sexually active as often as singles without ... older children. , The study, "Dating and Sexual Behavior ... States," was published online in the Journal of ...
(Date:9/23/2014)... 2014 PM360, a leading health-marketing industry ... industry with their annual Trailblazer Awards on Thursday, September ... at Gotham Hall in New York City, are given ... talent and brands. , “This industry ... Stashower, CEO and Publisher of PM360. “We are happy ...
(Date:9/23/2014)... 2014 The University of Maryland Medical System ... Court to pay $3 million for negligence during the delivery ... anterior arm [shoulder dystocia occurs after the delivery of the ... mother’s pelvic bone]. , On September 5, ... Uriah Evans, et. al. v. University of Maryland Medical Systems ...
Breaking Medicine News(10 mins):Health News:Opportunities to reduce patient burden associated with breast cancer screening 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 2Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 3
... a boost from a surprising source: the 2009 H1N1 pandemic ... strain developed antibodies that are protective against a variety of ... the University of Chicago have found. The results were published ... "Our data shows that infection with the 2009 pandemic ...
... , , Reproductive medicine is one of ... there are announcements of medical ,firsts, new rulings by ... heated debate among practitioners in the field, ethicists, legislators, ... is the forum where more than 9,000 of the ...
... News) -- Race and ethnicity play major roles in whether ... with minorities much less likely to undergo colonoscopies than white ... play: where people live. Research by oncologist Dr. ... Davis Cancer Center found that location makes a big difference ...
... January 10, 2011 -- While most blood tests require shipping a ... days for the results, a new device invented by a team ... just a pinprick of blood in a portable device that provides ... big step in point-of-care diagnostics, where testing can be performed in ...
... News) -- The first study to focus solely on the ... Sept. 11, 2001 attacks on the World Trade Center finds ... of the 3,271 evacuees of the Twin Towers surveyed in ... at least one current post-traumatic stress symptom, while 15 percent ...
... be most useful for clinical decision-making in trials in which ... recent study published online January 7 in The ... has been increasing interest in the value of patient-reported symptom ... secondary endpoints in new trials. Both the World Health Organization ...
Cached Medicine News:Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2Health News:Engineering team invents lab-on-a-chip for fast, inexpensive blood tests 2Health News:Many Survivors of World Trade Center Attacks Suffered PTSD: Study 2Health News:Quality of life measures in breast cancer clinical trials 2
Inquire...
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo...
Inquire...
Inquire...
Medicine Products: